Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 Extension Study
NCT01457118Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2011
- Primary completion
- Aug 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of etirinotecan pegol in solid tumor, sponsored by Nektar Therapeutics. Primary endpoint: Length of Exposure to NKTR-102. Started Oct 2011; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01457118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457118.